Yahoo Finance Live's Seana Smith breaks down the stocks trending in the after-hours trading session.
Is it time to bet on a turnaround?
Pharvaris NV (NASDAQ: PHVS) announced topline data from the RAPIDe-1 Phase 2 study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for hereditary angioedema (HAE) attacks. The study's primary endpoint is the change of a three-symptom composite (skin pain, skin swelling, abdominal pain) visual analog scale (VAS-3) score from pre-treatment to four hours post-treatment. Topline data from 147 attacks collected by 62 patients show that dose levels of PHVS416
After falling for much of the week, the major stock market indexes were gaining ground early Thursday as investors digested the latest unemployment numbers. Last week's initial jobless claims suggest the Federal Reserve's campaign to combat inflation may finally be bearing fruit. Investors used that positive development as an excuse to buy up their favorite beaten-down tech stocks.
The latest decision from ExxonMobil won't win any popularity contest, but it will make it a champion to its investors. On Thursday, the oil giant...
Have an issue with your financial adviser or looking to hire a new one? Email firstname.lastname@example.org.
Retirement-eligible salaried employees at Ford were warned about retiring this year to maximize a lump sum pension payment.
At age 51, Anne Schieber was broke and disillusioned. She had worked for the IRS for 23 years and was regarded as one of the agency’s top auditors. But she never got promoted and never earned more than $3,150 in a year. With half her life already behind her, her retirement prospects looked bleak. But Schieber had learned a powerful secret from years of studying the tax returns of America’s richest residents. Over the next 50 years, it earned her a 449,000% return — making Schieber one of the mos
Investors searching for that feeling telling you market sentiment is shifting to a more positive outlook have been brought down to earth again. Following 2022’s market behavior to a tee, the recent rally has run into a brick wall. To wit, the S&P 500 notched 5 consecutive negative sessions over the last week with investors mulling over the prospect of a recession. Indeed, financial experts have been sounding the warning bells on the precarious state of the global economy. One of the doomsayers h
The battery innovator is making progress on its lithium-metal batteries, but it still has a couple of years to go before it could start booking meaningful revenue.
ARK ETF Founder Cathie Wood joins Yahoo Finance Live for a wide-ranging interview on the state of the crypto market, Elon Musk, Fed policy, Teladoc, and more.
Shares of BioVie (NASDAQ: BIVI) were soaring 23.6% higher as of 11:19 a.m. ET on Thursday. The big jump appears to be the result of a delayed positive reaction by investors after the drugmaker reported results earlier this week from a phase 2 study evaluating experimental therapy NE3107. On Tuesday, BioVie's share price tumbled after the company's Monday evening announcement of results from its phase 2 study of NE3107 in treating Alzheimer's disease and Parkinson's disease.
Reconnaissance Energy Africa Ltd. (the "Company" or "ReconAfrica") (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) announces a conference call for investors and analysts will be held on Thursday, December 8, 2022 at 11:00 am Eastern Time. Participants will include Scot Evans, Chief Executive Officer, Dr. James Granath, Chief Geoscientist, and Grayson Andersen, Head of Capital Markets.
Buy and hold forever? Not always.
Shares of Summit Therapeutics (NASDAQ: SMMT) were skyrocketing 371.8% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. This huge gain came after the company announced on Tuesday that it's licensing bispecific antibody ivonescimab from Chinese drugmaker Akeso. Akeso will retain the rights to market the therapy throughout the rest of the world, including China.
The biotech industry can bring investors some truly lucrative gains – but these stocks are not for the faint of heart. The companies bring to the table a combination of famously high overhead and long product lead times, so investors will need to be patient with firms that regularly show long-term quarterly losses. But the rewards in biotech can change the game completely. A few catalysts – positive results from a clinical trial, approval from a governmental regulatory agency, or a new product l
Yahoo Finance's Jared Blikre highlights which stocks are making moves at the end of the trading session on Thursday.
Broadcom Inc. (AVGO) delivered earnings and revenue surprises of 1.75% and 0.38%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
(Bloomberg) -- The offer seemed too good to be true: Up to 200,000 barrels of heavy-sour crude at a $30 discount to the US benchmark. Most Read from BloombergPutin Calls Russian Nukes Deterrent Factor, Says War Risk RisingPeru’s President Accused of Coup After Move to Dissolve CongressWNBA Star Griner Freed in One-for-One Swap for Arms DealerElon Musk’s Bankers Consider Tesla Margin Loans to Cut Risky Twitter DebtWhy Did So Many US Men Quit Working? Social Status May Hold the Key, Study SaysThe